comparemela.com

Latest Breaking News On - Bi sky global ltd - Page 8 : comparemela.com

Innocan Pharma Announces the Addition of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Advisory Board

/PRNewswire/ Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pioneering pharmaceutical technology company.

Herzliya
Tel-aviv
Israel
Canada
Canadian
Josephv-pergolizzi-jr
Iris-bincovich
Company-or-innocan
Research-inc
Bi-sky-global-ltd
Innocan-pharma-corporation
Spain-associates

Innocan Pharma Announces Promising Results from Hair Care Cream Efficacy Test

/PRNewswire/ Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on.

Herzliya
Tel-aviv
Israel
Canada
Canadian
Iris-bincovich
Company-or-innocan
Prnewswire-innocan-pharma-corporation
Bi-sky-global-ltd
Innocan-pharma-corporation
Pharma-corporation
Central-nervous-system

Innocan Pharma Announces Promising Results from Hair Care Cream Efficacy Test

Innocan Pharma Announces Promising Results from Hair Care Cream Efficacy Test
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Israel
Canada
Herzliya
Tel-aviv
Canadian
Iris-bincovich
Innocan-pharma-corporation
Bi-sky-global-ltd
Company-or-innocan
Pharma-corporation
Central-nervous-system
Consumer-wellness

Innocan Pharma Announces Promising Results from Hair Care Cream Efficacy Test

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative wellness products, announced today the successful results of a controlled efficacy test (the "Trial") regarding its hair care cream (the "Product").

Canada
Canadian
Iris-bincovich
Innocan-pharma-corporation
Bi-sky-global-ltd
Central-nervous-system
Consumer-wellness
Joint-venture

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.